Market Cap : 276.52 B | Enterprise Value : 286.81 B | PE Ratio : 9.64 | PB Ratio : 3.16 |
---|
NYSE:PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Pfizer's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2022 was $39,624 Mil. Pfizer's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $84,816 Mil. Therefore, Pfizer's annualized ROE % for the quarter that ended in Jun. 2022 was 46.72%.
The historical rank and industry rank for Pfizer's ROE % or its related term are showing as below:
During the past 13 years, Pfizer's highest ROE % was 37.33%. The lowest was 10.23%. And the median was 17.20%.
PFE's ROE % is ranked better thanThe historical data trend for Pfizer's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pfizer's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pfizer's ROE % distribution charts can be found below:
* The bar in red indicates where Pfizer's ROE % falls into.
Pfizer's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (A: Dec. 2021 ) | / | ( (Total Stockholders Equity (A: Dec. 2020 ) | + | Total Stockholders Equity (A: Dec. 2021 )) | / count ) |
= | 21979 | / | ( (63238 | + | 77201) | / 2 ) | |
= | 21979 | / | 70219.5 | ||||
= | 31.30 % |
Pfizer's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as
ROE % | = | Net Income attributable to Common Stockholders (Q: Jun. 2022 ) | / | ( (Total Stockholders Equity (Q: Mar. 2022 ) | + | Total Stockholders Equity (Q: Jun. 2022 )) | / count ) |
= | 39624 | / | ( (82424 | + | 87208) | / 2 ) | |
= | 39624 | / | 84816 | ||||
= | 46.72 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE %** | (Q: Jun. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 39624 | / | 84816 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (39624 / 110968) | * | (110968 / 189565.5) | * | (189565.5 / 84816) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 35.71 % | * | 0.5854 | * | 2.235 |
= | ROA % | * | Equity Multiplier | ||
= | 20.9 % | * | 2.235 | ||
= | 46.72 % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE %** | (Q: Jun. 2022 ) | ||||||||
= | Net Income | / | Total Stockholders Equity | ||||||
= | 39624 | / | 84816 | ||||||
= | (Net Income /Pre-Tax Income) | * | (Pre-Tax Income/Operating Income) | * | (Operating Income/Revenue) | * | (Revenue/Total Assets) | * | (Total Assets/Total Stockholders Equity) |
= | (39624 / 45788) | * | (45788 / 49636) | * | (49636 / 110968) | * | (110968 / 189565.5) | * | (189565.5 / 84816) |
= | Tax Burden | * | Interest Burden | * | Operating Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 0.8654 | * | 0.9225 | * | 44.73 % | * | 0.5854 | * | 2.235 |
= | 46.72 % |
Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
Net income attributable to common stockholders is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of Pfizer's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Denton David M | officer: Chief Financial Officer & EVP | 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117 |
Pao William | officer: Executive Vice President | C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Mcdermott Michael | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017 |
Malik Aamir | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Carapezzi William R Jr | officer: Executive Vice President | 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921 |
Sahni Payal | officer: Executive Vice President | ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017 |
Desmond-hellmann Susan | director | 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143 |
Hockfield Susan | director | GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210 |
Damico Jennifer B. | officer: SVP & Controller | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Quincey James | director | THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 |
Gottlieb Scott | director | MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142 |
Fonseca Lidia | officer: Executive Vice President | 358 SOUTH MAIN STREET BURLINGTON NC 27215 |
Goettler Michael | officer: Group President | 1000 MYLAN BOULEVARD CANONSBURG PA 15317 |
Rogers Dawn | officer: Executive Vice President | 235 EAST 42ND STREET NEW YORK NY 10017 |
Littman Dan R. | director | ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017 |
Other Sources
By tipranks.com 2022-03-25
By Zacks 2022-03-25
By tipranks.com 2022-04-01
By Zacks 2022-03-22
By Zacks 2022-03-29
By tipranks.com 2022-03-25
By Zacks 2022-03-30
By Zacks 2022-03-23
By Zacks 2022-04-04
By Zacks 2022-03-24
By Zacks 2022-04-04
By Zacks 2022-04-04